We used the selected population of patient-derived pMMR (high expressions of MLH1, MSH2, and MSH6) CRC xenografts (Supplementary Fig. 3), and further divided these xenografts into two subgroups based on their ABHD5 expression proficiency (Supplementary Fig. 3). This evidence concerns the gene MSH2 and colorectal carcinoma.